Literature DB >> 17150185

Characterization of a novel oncogenic K-ras mutation in colon cancer.

Kiwamu Akagi1, Ryosuke Uchibori, Kensei Yamaguchi, Keiko Kurosawa, Yoichiro Tanaka, Tomoko Kozu.   

Abstract

Activating mutations of RAS are frequently observed in subsets of human cancers, indicating that RAS activation is involved in tumorigenesis. Here, we identified and characterized a novel G to T transversion mutation of the K-ras gene at the third position of codon 19 (TTG) which substituted phenylalanine for leucine in 3 primary colon carcinomas. Biological and biochemical activity was examined using transformed NIH3T3 cells expressing mutant or wild-type K-ras. Transformants harboring the K-ras mutation at codon 19 showed proliferative capacity under serum-starved conditions, less contact inhibition, anchorage-independent growth, tumorigenicity in nude mice and elevation of active Ras-GTP levels. These results indicated that this novel mutation possesses high oncogenic activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17150185     DOI: 10.1016/j.bbrc.2006.11.091

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.

Authors:  Shigenori Kadowaki; Miho Kakuta; Shuhei Takahashi; Akemi Takahashi; Yoshiko Arai; Yoji Nishimura; Toshimasa Yatsuoka; Akira Ooki; Kensei Yamaguchi; Keitaro Matsuo; Kei Muro; Kiwamu Akagi
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

2.  Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.

Authors:  Kent W Mouw; James M Cleary; Brendan Reardon; Jonathan Pike; Lior Z Braunstein; Jaegil Kim; Ali Amin-Mansour; Diana Miao; Alexis Damish; Joanna Chin; Patrick A Ott; Charles S Fuchs; Neil E Martin; Gad Getz; Scott Carter; Harvey J Mamon; Jason L Hornick; Eliezer M Van Allen; Alan D D'Andrea
Journal:  Clin Cancer Res       Date:  2016-11-16       Impact factor: 12.531

3.  Genetic alterations in Japanese extrahepatic biliary tract cancer.

Authors:  Rei Noguchi; Kiyoshi Yamaguchi; Tsuneo Ikenoue; Yumi Terakado; Yasunori Ohta; Naohide Yamashita; Osamu Kainuma; Sana Yokoi; Yoshiaki Maru; Hiroki Nagase; Yoichi Furukawa
Journal:  Oncol Lett       Date:  2017-05-22       Impact factor: 2.967

4.  Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples.

Authors:  Heather Sanders; Kevin Qu; Hairong Li; Lin Ma; Cindy Barlan; Xi Zhang; James Prentice; David Wolfson; Beryl Crossley; Anthony Sferruzza; John Sninsky; David Ross; Andrew Grupe; Joseph Catanese; Feras Hantash; Frederic Waldman
Journal:  Mol Diagn Ther       Date:  2016-06       Impact factor: 4.074

5.  Activation of K-RAS by co-mutation of codons 19 and 20 is transforming.

Authors:  Adam Naguib; Catherine H Wilson; David J Adams; Mark J Arends
Journal:  J Mol Signal       Date:  2011-03-03

6.  Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer.

Authors:  Bixiang Zhang; Sunil K Halder; Sanguo Zhang; Pran K Datta
Journal:  Cancer Lett       Date:  2009-01-14       Impact factor: 8.679

7.  Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.

Authors:  G Smith; R Bounds; H Wolf; R J C Steele; F A Carey; C R Wolf
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

Review 8.  Mechanistic regulation of epithelial-to-mesenchymal transition through RAS signaling pathway and therapeutic implications in human cancer.

Authors:  Kiran Tripathi; Minal Garg
Journal:  J Cell Commun Signal       Date:  2018-01-12       Impact factor: 5.782

9.  Fast simultaneous detection of K-RAS mutations in colorectal cancer.

Authors:  Ya-Sian Chang; Kun-Tu Yeh; Tien-Jye Chang; Connie Chai; Hsiu-Chin Lu; Nicholas C Hsu; Jan-Gowth Chang
Journal:  BMC Cancer       Date:  2009-06-11       Impact factor: 4.430

10.  KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition.

Authors:  E Rouleau; F Spyratos; B Dieumegard; J M Guinebretière; R Lidereau; I Bièche
Journal:  Br J Cancer       Date:  2008-12-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.